Latest Disease-modifying antirheumatic drug Stories
FIRST OF SEVERAL PHASE 3 TRIALS TO REPORT RESULTS INDIANAPOLIS, Dec.
The Imminent Entry of Biosimilars Will Constrain Sales of Branded Biologics and Premium-Priced Emerging Agents, According to Findings from Decision Resources Group BURLINGTON, Mass., Sept.
Achieve is conducting a multicenter, randomized, single-dose study assessing the pharmacodynamic parameters of an experimental combination therapy in
New research shows mortality rates are two times higher in postmenopausal women with rheumatoid arthritis (RA) and anti-cyclic citrullinated peptide (anti-CCP) antibodies.
Achieve is conducting a study to evaluate the safety and efficacy of a new drug versus rituximab in patients with moderately to severely active
New results from the National Health and Wellness Survey show few eligible patients are using biologic treatments. New York, NY (PRWEB) September 14, 2013
- A member of the swell-mob; a genteelly clad pickpocket. Sometimes mobsman.